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Abstract: 
The 2,11-cembranoid family of natural products has been used as 
inspiration for the synthesis of a structurally simplified, functionally 
diverse library of octahydrobenzofuran based compounds designed 
to augment a typical medicinal chemistry library screen. Ring-closing 
metathesis, lactonisation and SmI2 mediated methods were 
exemplified and applied to installation of a third ring to mimic the 
nine-membered ring of the 2,11-cembranoids. The library was 
assessed for aqueous solubility and permeability, with a chemical 
space analysis performed for comparison to the family of 
cembranoid natural products and a sample set of a screening library. 
Preliminary investigations in cancer cells showed that the simpler 
scaffolds could recapitulate the reported anti-migratory activity of the 
natural products. 
Introduction 
The 2,11-cembranoids are a structurally complex family of 
natural products isolated from the Octocorallia species, 
consisting of a polyoxygenated 2,11-cyclised diterpenoid core 
scaffold.1 The structures are further subcategorised into 
cladiellins 1, briarellins 2 and asbestinins 3 (Figure 1). Due to 
their structural complexity and broad ranging biological activities, 
the members of the structural class have been and continue to 
be attractive targets for total synthesis.2-17 By necessity, such 
approaches require multi-step routes, with a particular challenge 
being introduction of the 9-membered cyclic ether ring and the 
installation of the specific complex substitution patterns 
associated with each natural product. Methods used to form 
such a ring include Nozaki-Hiyama-Kishi coupling,7,8,11,14 Claisen 
ring expansion,6 ring-closing metathesis (RCM),4,9,13,15 diazo 
ketone cyclisations10,16 and oxidative ring expansion.17 A number 
of these total synthesis routes have been shown to afford 
access to more than one member of the natural product 
family5,7,8,10,11,13,17 allowing the preparation of small libraries of 
the natural products. The broad ranging biological activities of 
the cembranoid family have been reviewed,1 and have been 
found to encompass anticancer, anti-inflammatory, antiviral and 
antibacterial properties, amongst others.  
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Figure 1. Cladiellin, Briarellin and Asbestinin core scaffolds. Carbons bearing 
an asterisk are commonly oxygenated or unsaturated within the class. 
Natural products have been a great source of inspiration in drug 
discovery, being used either in their own right as drugs or as the 
starting point for drug discovery projects.18 Libraries of natural 
products, natural product inspired or other structurally complex 
scaffolds have been shown to be a rich source of hits in 
phenotypic screens,19 which probe phenotypes arising from 
biological manipulation with small molecules in cells or small 
organisms (for example, zebra fish embryos20). As biological 
assay screening tools they frequently occupy complementary 
chemical space to commercially available synthetic libraries, 
providing novelty from both a structural and intellectual property 
perspective.21 Those natural products found to display 
interesting biological activities can, however, be 
stereochemically complex molecules, thus presenting significant 
synthetic challenges regarding analogue synthesis. Numerous 
approaches have been taken to overcome such challenges, in 
particular Diversity Oriented Synthesis (DOS),19,22 Biological 
Oriented Synthesis (BIOS)23 and Lead-oriented Synthesis.24 A 
principal challenge is to retain structural features of the natural 
products that differentiate them from chemical space explored 
by traditional small molecule screening libraries, and may be 
associated with the bioactivities of the natural  products, while 
simplifying the structures to give easier synthetic access and 
control of physicochemical properties. 
 
Within the context of drug discovery, numerous metrics have 
been suggested as design aids in attempts to predict the 
likelihood of drugability,25 one of the most prevalent being 
Lipinski’s rule-of-five.26 The central tenet of many of these 
metrics is to predict the ability of a compound to dissolve in 
aqueous media and to pass through a lipid membrane, both 
properties that may also be readily measured. To be useful for 
cell or organism-based biology, compounds must be sufficiently 
cell permeable and water soluble. It is therefore desirable to 
design new libraries around scaffolds where these properties are 
intrinsic. 
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Here, we present the synthesis of a 2,11-cembranoid inspired 
small library of compounds, designed to retain the biological 
activities of the natural product class within structurally simplified 
library analogues, whilst displaying desirable lead-like properties. 
The cembranoid class of natural products have demonstrated 
multiple biological activities in cells and parasites,1 making the 
core scaffold an ideal starting point to make libraries of cell 
permeable compounds. It was envisaged that the 
octahydrobenzofuran core, with and without the third fused 
medium ring from the 2,11-cembranoid motif, could be used as a 
privileged structure.28 It was anticipated that the library of 
compounds produced from such a privileged core would be able 
to recapitulate some of the biological activities observed in the 
natural product class, whilst reducing the synthetic complexity. 
The main synthetic challenge, therefore, was to find quick and 
concise routes to introduce substituent variation around the 
chosen core and methods to install a third ring system to mimic 
the nine-membered ring of the 2,11-cembranoids.  
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Scheme 1. Library design and retrosynthetic analysis 
From the many successful synthetic strategies exemplified for 
the 2,11-cembranoid natural products, we chose to explore a 
Diels-Alder reaction to construct the [6,5]-bicyclic core of the 
library6,7 We anticipated a rapid and flexible entry to the 
octahydrobenzofuran scaffold through Diels Alder cyclisation, 
with the potential to vary substituent patterns through choice of 
starting materials or manipulation of intermediates. Such an 
approach would provide a platform to investigate both 
functionalization of the bicycle as well as installation of a 
medium or larger ring equivalent to the nine-membered ring of 
the natural products. The retrosynthetic approach is as outlined 
in Scheme 1. From (S)-5-(hydroxymethyl)-2(5H)-one 9, Diels 
Alder reaction with a range of dienes was envisaged to install 
the [6,5] core of 7, which can be further manipulated to produce 
bicyclic analogues of general structure 5, or further cyclised to 
tricyclics such as 4. Following generation of the library, aqueous 
solubility, permeability and structural diversity in relation to in-
house screening libraries were assessed. In addition, the ability 
to recapitulate some of the biological activity of the more 
complex natural products with simpler structures from the library 
was demonstrated.  
 
Results and Discussion 
Protection of commercially available alcohol 9 with TBDPSCl 
gave lactone 8 in 87% yield; chiral HPLC confirmed the 
presence of a single enantiomer (Scheme 2). Reaction of silyl 
ether 8 with butadiene in the presence of AlCl3 in 
dichloromethane at 55 ºC in a sealed tube for one week under 
literature conditions29 gave bicyclic 10 in 40% yield. Although 
forming the desired product, yields were found to be highly 
variable. Screening of a number of Lewis Acids found 
TfN(AlMeCl)230 to give a consistently high yield of around 70-
80% after a two day reaction. Furthermore, it was found possible 
to use a solution of 30% butadiene in toluene as the diene 
source, avoiding the inconvenience and hazards associated with 
condensing gaseous butadiene. Reduction of lactone 10 with 
DIBAL-H gave lactol 11 in high yield, which in turn was reacted 
with allyltrimethylsilane31,32 to give 12 as a single enantiomer. 
The exclusive cis selectivity from reaction of the bicyclic lactol 11 
contrasts with literature examples of monocyclic lactols, where 
the trans isomer predominates from an intermolecular 
allyltrimethylsilane addition.30 The observed difference can be 
rationalised by looking at a proposed conformation of oxonium 
intermediate 13, where the least hindered approach from the 
nucleophile leads to the cis product 12. 
 
Deprotection of silyl ether 12 using TBAF gave alcohol 14 in 
82% yield, which was esterified to form esters of various chain 
lengths 15, 16, 17 and 18. Following considerable opimisation, 
ring closing metathesis (RCM) cyclisation using Grubbs II 
catalyst at high dilution in dichloromethane gave tricyclics 20, 21 
and 22. Nine-membered lactone 19 could not be formed, 
whereas 10-membered lactone 20 was produced in low yield. 
The alkene conformation of 20 was presumed to be cis due to 
the strain of a trans double bond in such a 10-membered lactone. 
The larger, less strained 11- and 12-membered lactones were 
more readily constructed. The alkene conformation of 21 was 
undetermined due to overlapping NMR signals, whereas 22 was 
assigned trans by analogy to the crystal structure conformations 
of 40 and 42 (vide infra). By using a similar reaction sequence, 
but reducing the alkene of 10 earlier in the route, cyclohexane 
analogues 26, 27 and 28 were also formed. The structure of 26 
was confirmed by X-ray crystallography (see supplementary 
information).  
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Scheme 2. Reagents and Conditions: a) TBDPSCl, imidazole, DMF, 0 ºC-rt, 
2.5 h, b) butadiene, TfN(AlMeCl)2, CH2Cl2, 60 ºC, c) DIBAL-H, CH2Cl2, -78 
ºC, d) allylTMS,BF3.OEt2, -78 ºC, e) TBAF, 0 ºC, f) acid chloride, pyridine or 
Et3N g) Grubbs II, 0.0005 M CH2Cl2, rt h) Pd/C (5 wt%), H2, EtOAc, rt. 
As lactone 19 could not be formed, speculated to be due to the 
transoid nature of the ester in 15 adding to the strain in forming 
a 9-membered ring, synthesis of the ether analogue 30 was 
attempted (Scheme 3). Alkylation of alcohol 14 with allyl bromide 
gave cyclisation precursor 29. However, no RCM product could 
be observed under the above optimised conditions, highlighting 
the difficulty in forming the strained 9-membered ring. Previous 
RCM approaches to 9-membered ring formation in the context of 
2,11-cembranoid synthesis have met with mixed success,3,4,15,33 
and appear highly substrate dependant.  
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Scheme 3. Reagents and Conditions: a) NaH, allylbromide, b) Grubbs II, 
0.0005 M, CH2Cl2, rt. 0%.  
Using the alkene functionality of lactone 10 as a point of 
derivatisation, dihydroxylation of the alkene from the least 
sterically crowded face using catalytic osmium tetroxide followed 
by dimethylacetal protection gave tricyclic 31 in 52% yield over 
two steps (Scheme 4). Using a similar sequence to that shown 
in Scheme 2, lactone 31 was reduced to lactol 32, reacted with 
allyltrimethylsilane in the presence of BF3.OEt2 and deprotected 
to alcohol 33. Esterification, ring closing metathesis and acetal 
deprotection with acid gave diol 36. 
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Scheme 4. Reagents and Conditions: a) OsEnCat (0.5 mol%), NMO b) 2,2-
dimethoxypropane, PPTS, c) DIBAL-H, -78 ºC d) allylTMS, BF3.OEt2, -78 ºC 
e) TBAF, f) hex-5-enoyl chloride, py, CH2Cl2, g) Grubbs II, 0.0005 M CH2Cl2, 
h) HCl, THF. 
Analogue synthesis by changing the diene component was also 
demonstrated (Scheme 5). Using 2-methylbutadiene gave an 
85:15 inseparable mix of methyl regioisomers (major isomer 37 
shown). The major 5-methyl component was isolated following 
oxidative hydroborylation to give alcohol 38. As above, alcohol 
38 was in turn converted to lactone 39. As further 
exemplification of diene variations in the Diels Alder reaction, 
cyclohexa-1,3-diene and cyclopentadiene were used to make 
tetracyclics 40, 41 and 42. Confirmation of the structure of 40 
and 42 was achieved by X-ray crystallography (see 
supplementary information). During the synthesis of 42, it was 
found necessary to reduce the alkene derived from the diene 
due to undesired ring opening occurring in the subsequent RCM 
reaction, presumably as a consequence of release of inherent 
ring strain in the embedded cyclopentene ring that was not 
present in the cyclohexene analogue.  
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Scheme 5. Reagents and Conditions: a) TfN(AlMeCl)2, CH2Cl2, 60 ºC, 100% 
b) BH3.THF, then H2O2, H2O 55%.  
The Mukaiyama aldol reaction on lactol 11 provided a means of 
introducing further substitution and a handle for elaboration. To 
this end, adducts of general structure 43 were formed as single 
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enantiomers by reacting hemiacetal 11 with a range of silyl enol 
ethers. As in the example of allyltrimethylsilane addition above 
(Scheme 2), the cis products were observed exclusively or as 
the major component (85:15 in the formation of 48). Silyl ethers 
44, and 45 were obtained, as well as alcohols 46, 47 and 48 
following silyl deprotection (Scheme 6).  
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Scheme 6. Reagents and Conditions: a) Silyl enol ether, BF3.OEt2 (TMSOTf 
for 46), CH2Cl2, -78 ºC 36-97%. 
With aldehyde 44 in hand, derivation was exemplified either by 
reduction to diol 49, or through reductive amination with the 
amines listed in Scheme 7. Deprotection of the amines 50-54 
with TBAF provided alcohols 55-59 in good yield.  
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Scheme 7. Reagents and Conditions: a) NaBH4, THF, MeOH 82% b) TBAF, 
THF, 41-93% c) amine, NaBH(OAc)3, DCE, 52-64% d). PhSiMe3, AuCl(PPh3), 
Selectfluor, MeOH, MeCN, then TBAF 29%. 
Modification of the terminal olefin in 24 was also exemplified. 
Oxyarylation34 using a gold (I) catalyst in the presence of 
Selectfluor with phenyltrimethylsilane gave ether 60 as an 
inseparable 4:1 mix of diastereomers (Scheme 7).  
 
An alternative lactonisation approach to forming an oxygen 
containing nine-membered ring system and thus provide library 
members with closer correspondence to the [6,5,9]-tricyclic core 
of the natural product family was attempted from aldehyde 44. A 
Horner-Wadsworth-Emmons reaction gave α,β-unsaturated 
ester 61 (Scheme 8). Reduction of both alkenes by 
hydrogenation over palladium gave ester 62. Deprotection of the 
silyl group with TBAF followed by ester hydrolysis gave acid 64 
in 71% over two steps. Lactonisation was initially attempted 
using the Yamaguchi protocol,35 via the intermediate 2,4,6-
trichlorobenzoyl anhydride. None of the desired lactone was 
observed in a number of attempts, with a dimeric species the 
only isolated product seen. A more successful approach used 
conditions developed by Shiina,36 whereby a solution of acid 64 
was added slowly by syringe pump over a 15 h period to a 
solution of 2-methyl-6-nitrobenzoic anhydride and DMAP in 
dichloromethane. Using these conditions, lactone 65 was 
isolated in 30% yield. Interestingly, an IR absorption for the 
carbonyl group was observed at 1730 cm-1, suggesting the 
carbonyl group to be significantly twisted out of plane from the 
lowest energy lactone conformation (cf. crystal structure of 69, 
Figure 2).  
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Scheme 8. Reagents and Conditions: a) triethylphosphonoacetate, NaH, THF, 
b) Pd/C, EtOAc, H2 c) TBAF, THF, d) LiCl, H2O, THF, e) 2-methyl-6-
nitrobenzoic anhydride.  
A SmI2-mediated Reformatsky reaction approach was also 
found successful in the synthesis of a 9-membered lactone. The 
Reformatsky reaction has been shown previously to give high 
yields and controlled stereochemistry in the synthesis of a 
variety of natural product ring systems,37 and more pertinently in 
medium ring synthesis.38 Here, alcohol 23 was subjected to the 
Mukaiyama aldol/TBAF deprotection sequence used above to 
give unstable alcohol 67 (Scheme 9). Bromoacetyl bromide 
acylation followed by SmI2 induced cyclisation gave alcohol 69 
in 45% yield. In addition, alcohol 69 could be further derivatised 
if required, such as to acetate 70. The structure and absolute 
stereochemistry of 69 was confirmed by crystallography (Figure 
2). As with lactone 65, an unusual IR carbonyl stretch of 1723 
cm-1 was observed for 69 as a consequence of a 33º twist out of 
conjugation with the ester oxygen. 
 
With synthetic routes to 9-membered lactones in hand, focus 
returned to accessing 9-membered ethers. Starting from alcohol 
25, synthesised as shown in Scheme 2, oxidation to aldehyde 
71 and subsequent reaction with but-3-en-1-ylmagnesium  
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Scheme 9. Reagents and Conditions: a) BF3.OEt2, trimethyl((2-methylprop-1-
en-1-yl)oxy)silane, CH2Cl2, -78 ºC-rt, b) TBAF, THF c) bromoacetyl bromide, 
Et3N, CH2Cl2, 34% over three steps d) SmI2, THF, e) Ac2O, DMAP, rt.  
 
Figure 2. X-ray crystal structure of 42 (a), 40 (b), 69 (c) and a partial view of 
69 (d) along the O-C lactone single bond. 
 bromide gave alcohols 72 and 73 as a 5:3 separable mixture of 
isomers (Scheme 10). Following TBS protection, only the major 
isomer 72 was found to cyclise in the RCM reaction, giving 
tricyclic 75 in 97% yield. A NOESY correlation between both 
[6,5] bridgehead hydrogens and the siloxy substituted C-H 
hydrogen in 75 as highlighted in Figure 3 was used to confirm 
the sterochemistry of Grignard addition. Deprotection with TBAF 
gave alcohol 76 in 55% yield. 
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Scheme 10. Reagents and Conditions: a) Dess Martin reagent, CH2Cl2 b) 
but-3-en-1-ylmagnesium bromide, THF c) TBSOTf, DIPEA, CH2Cl2, d) Grubbs 
II (10 mol%), CH2Cl2, reflux, e) HCl, EtOH, Et2O. 
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Figure 3. 1H-1H NOESY correlations in tricyclic 75. 
The 2,11-cembranoid based library of 44 compounds 
synthesised using the routes and methods outlined above is 
shown in full in Figure 4. As the compounds were intended for 
use in drug discovery screening programmes, an assessment of 
the library in terms of structural diversity, physicochemical 
properties and potential biological activity was undertaken. An 
analysis of the molecular properties of the compounds in Figure 
4 is compiled in Table 1. For comparison, the properties of 183 
cembranoid natural products taken from reviews1,39 and a 
random sampling set of 358 compounds taken from a 
substantially larger 75000 screening library at The Institute of 
Cancer Research (ICR) are also listed for comparison. The 
ability of a random sampling set of a large screening library to 
represent the entirety has been demonstrated by Feher and 
Schmidt,21 and has been applied here. The ICR screening library 
itself was chosen by typical criteria for lead-like/drug like libraries, 
including limits on predicted/calculated physicochemical 
parameters and choice of scaffolds, with a high frequency of 
heterocyclic aromatic and aliphatic scaffolds26,27. As a means of 
visually assessing the diversity between the groups, a principal 
component analysis (PCA)41 was performed. PCA has been 
used widely in chemoinformatics42 and particularly in the 
description of chemical space.22,43 The analysis, carried out 
using SIMCA-P+44 and visualised using Spotfire,45 showed 
(Figure 5) that the ICR screening compounds (red) cover a wide 
range of chemical space as would be expected from a well 
designed screening deck; however, little overlap exists with the 
cembranoid natural products (blue) which occupied a discrete 
and well defined region defined by the PCA. By contrast, the 
cembranoid-inspired library as synthesised here (green) was 
found to occupy an area of chemical space between the natural 
products and the ICR screening collection, showing that the 
cembranoid-inspired library begins to effectively bridge the 
chemical space between classical drug discovery screening 
compounds and the natural products. 
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Figure 4. Cembranoid-like library 
Table 1. Arithmetic mean and standard deviation of the molecular properties 
of the cembranoid-inspired library, 2,11-cyclised cembranoid natural products 
and a random sampling set from The Institute of Cancer Research screening 
collection. 
 
Cembranoid-
inspired library 
2,11-cyclised 
Cembranoids 
ICR Screening 
Collection sample 
No. of compounds 44 183 358 
MW  275 (28) 441 (77) 332 (59) 
AlogP 2.6 (0.8) 3.1 (1.1) 2.6 (1.1) 
No. H acceptors  3.2 (0.7) 6.4 (2.0) 4.1 (1.4) 
No. H donors  0.7 (0.8) 1.0 (0.9) 1.1 (0.8) 
No. rings 2.6 (0.6) 3.4 (0.6) 2.9 (0.9) 
No. aromatic rings  0.07 (0.26) 0 (0) 2.0 (1.0) 
No. Oxygen atoms 3.1 (0.7) 6.4 (2.0) 2.4 (1.4) 
No. hydrogen 
atoms 
25 (2.9) 39 (5.9) 18 (5.3) 
No. Stereoatoms 4.7 (0.9) 8.9 (1.5) 0.04 (0.33) 
No. bonds 21 (2.2) 34 (5.4) 25 (4.7) 
No. Aromatic 
bonds 
0.43 (1.6) 0 (0) 11 (5.2) 
No. rotatable 
bonds 
4.8 (3.2) 5.9 (3.1) 4.5 (2.0) 
 
 
Figure 5. Principal component analysis (PCA) of the cembranoid-inspired 
library (green, 44 structures), 2,11-cyclised cembranoid natural products (blue, 
183 structures) and the ICR screening sample (red, 358 structures). 
Performed using SIMCA-P+44 and displayed using Spotfire.45 
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The library prepared was assessed for both solubility and 
permeability, with representative results shown in Table 2. Due 
to a lack of UV chromophore and/or poor mass spectrometry 
ionisation, nephelometry46 was used to measure solubility. 
PAMPA (parallel artificial membrane permeability assay)47 was 
used to assess permeability. Generally, the compounds were 
found to have high aqueous solubility and permeability. Of the 
44 compounds in Figure 4, all were measured to have greater 
that 100 uM aqueous solubility, with 34 greater than 500 uM and 
21 greater than 1000 uM. In regard to the 28 compounds that 
ionised sufficiently well to be detected in PAMPA, 25 were found 
to have high permeability, greater than 25x10-6 cms-1. For the 
specific example of compound 28 in addition to good aqueous 
solubility and high PAMPA, the compound showed moderate 
permeability across a monolayer of Caco-2 human intestinal 
cancer cells,48 (16x10-6 cms-1) with no evidence of transporter 
efflux. 
 
Table 2. Solubility and permeability of selected  representative compounds 
 compounds 
 28 15 65 76 
Sol (uM) 550 500 550 500 
Permeability 
(Pe, x10-6 cms-1) 
52 25 >150 Not 
detecteda 
Solubility measured by nephelometry. Eqm indicates maximum permeability 
achieved within the assay timescale. n.d. not done. a indicates undetectable 
due to low ionisation.  
A selection of 15 of the cembranoid inspired compounds were 
screened against a panel of 60 cancer cell lines at the National 
Cancer Institute screening panel (see supporting information).49 
This cell-based assay aims to discover compounds with a strong 
cytostatic or cytotoxic growth inhibition over 48 hours. 
Unfortunately, only low levels (up to 20%) of cell growth 
inhibition were seen when screened at a single concentration of 
10 uM. Of these, compound 28 gave 17% inhibition of 
proliferation in the PC3 human prostate cancer cell line. A full 
dose response curve obtained for compound 28 (Figure 6) found 
a GI50 of 63 uM. It is important to note that the cembranoid 
family itself is not overtly cytotoxic, with most examples 
screened to date ranging from single figure micromolar IC50 to 
inactive in the cytotoxic assays used.1 One obvious exception to 
this is sclerophytin A, with in vitro IC50 of 3 nM in L1210 mouse 
lymphocytic leukemia cells,51 although the natural product 
showed no effect on proliferation in PC3 cells at 50 uM. 
Therefore, within this context, compound 28 displays typical 
cytotoxicity for the natural product family,39 with reduced 
structural and synthetic complexity.  
 
Whereas cembranoid natural products may not be inherently 
cytotoxic, an appreciable number do display an ability to inhibit 
the migratory and invasive properties of cancer cells.50 The 
effect of compound 28 on a PC3 based migratory assay was 
therefore determined. Tricyclic 28 at 3- and 5-fold GI50 
concentrations demonstrated a reduction to near basal levels of 
migration (Figure 6). Although less potent than a number of the 
2,11-cembranoid natural products (most active being 
sclerophytin A, with 85% inhibition of migration at 50 uM),50 it 
does demonstrate that the anti-migratory activity can be retained 
in a greatly simplified structural motif.  
 
 
Figure 6. 1) Concentration-response curve for the antiproliferative effect of 28 
on PC3 cells in vitro 96 h assay. 2) Compound 28 inhibiting the migration 
properties of PC3 TEM cancer cells. FCS- fetal calf serum. Y-axis shows fold-
change in cell migration normalised to the absence of FCS. 
Conclusions 
The 2,11-cembranoid class of natural products has served as a 
rich source of inspiration from both a synthetic and biological 
perspective. Here, we have developed a number of synthetic 
approaches to produce a library of structurally simplified 
cembranoid inspired derivatives. An assessment of the 
molecular properties of the hexahydroisobenzofuran-based 
library found them to be complementary to both the cembranoid 
natural products as well as a sample set of an in-house 
medicinal chemistry screening collection, providing potential 
access to novel chemical space. A screen of physicochemical 
properties found the library to have desirable properties, namely 
aqueous solubility and cell membrane permeability, essential to 
be useful in both biochemical and cell based assays. The 
illustrative synthetic routes developed could readily be expanded 
to more densely populate the chemical space occupied by the 
small library and the natural products, or indeed to follow up any 
hits from future screening. A preliminary screen of a sample set 
of the library found compound 28 to weakly inhibit the growth of 
PC3 cells, as well as having an inhibitory effect when screened 
in a cell migration assay. These data suggest that some of the 
bioactivities observed in cancer cells for the structurally complex 
2,11-cembranoid natural products can be recapitulated with 
much simpler scaffolds derived from the embedded 
hexahydroisobenzofuran core. 
Experimental 
All synthetic methods are included in the Supplementary section. 
Crystallographic data is available free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
CCDC numbers; 26 CCDC 1010197, 40 CCDC 1011320, 42 CCDC 1435146, 
69 CCDC 1435148. 
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